STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER

被引：0

作者：

Enriquez-Aceves, Isabel ^{[1
]}

Galicia-Carmona, Tatiana ^{[2
,3
]}

Coronel-Martinez, Jaime A. ^{[2
,3
]}

Espinosa-Romero, Raquel ^{[3
]}

Calderillo-Ruiz, German ^{[3
]}

Cortes-Esteban, Patricia ^{[4
]}

Cetina-Perez, Lucely ^{[2
,3
]}

机构：

[1] Hosp Inst Seguridad & Serv Sociales Trabajadores, Dept Med Oncol, Leon, Gto, Mexico

[2] Inst Nacl Cancerol, Dept Clin Res, Mexico City, DF, Mexico

[3] Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico

[4] Ctr Med Nacl 20 Noviembre, Dept Med Oncol, Mexico City, DF, Mexico

来源：

REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2020年 / 72卷 / 04期

关键词：

Bevacizumab; Cervical; Cancer; Metastatic antiangiogenic; PHASE-II TRIAL; SQUAMOUS-CELL-CARCINOMA; COMBINATION THERAPY; 3RD-LINE TREATMENT; OPEN-LABEL; RECURRENT; PERSISTENT; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL;

D O I：

10.24875/RIC.20000061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.

引用

页码：213 / 218

页数：6

共 50 条

[1] Advances in Targeted Therapy for the Treatment of Cervical Cancer
Watkins, Dean E.
Craig, Daniel J.
Vellani, Shahnaz D.
Hegazi, Ahmad
Fredrickson, Kaylee J.
Walter, Adam
Stanbery, Laura
Nemunaitis, John
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (18)
[2] Targeted Agents in Cervical Cancer: Beyond Bevacizumab
Gloria Marquina
Aranzazu Manzano
Antonio Casado
Current Oncology Reports, 2018, 20
[3] Targeted Agents in Cervical Cancer: Beyond Bevacizumab
Marquina, Gloria
Manzano, Aranzazu
Casado, Antonio
CURRENT ONCOLOGY REPORTS, 2018, 20 (05)
[4] Bevacizumab for the treatment of cervical cancer
Bizzarri, Nicolo
Ghirardi, Valentina
Alessandri, Franco
Venturini, Pier Luigi
Menada, Mario Valenzano
Rundle, Stuart
Maggiore, Umberto Leone Roberti
Ferrero, Simone
EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 407 - 419
[5] Bevacizumab and treatment of cervical cancer
Kehoe, Sean
MATURITAS, 2014, 79 (04) : 355 - 356
[6] Targeted therapy in cervical cancer
Vora, Chakor
Gupta, Sudeep
ESMO OPEN, 2018, 3
[7] VEGF - targeted therapy for the treatment of cervical cancer - literature review
Salomon-Perzynska, Magdalena
Perzynski, Aleksander
Rembielak-Stawecka, Beata
Michalski, Bogdan
Skrzypulec-Plinta, Violetta
GINEKOLOGIA POLSKA, 2014, 85 (06) : 461 - 465
[8] Targeted therapy of colorectal cancer: Clinical experience with bevacizumab
Fernando, NH
Hurwitz, HI
ONCOLOGIST, 2004, 9 : 11 - 18
[9] Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
Georgios V. Koukourakis
Anastasia Sotiropoulou-Lontou
Clinical and Translational Oncology, 2011, 13 : 710 - 714
[10] Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
Koukourakis, Georgios V.
Sotiropoulou-Lontou, Anastasia
CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (10): : 710 - 714

← 1 2 3 4 5 →